STOP

Before opening this package, please read the Limited Use License statement below:

Important Limited Use License information for pCpGfree-vitroBmcs

The purchase of the pCpGfree-vitroBmcs vector conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes.

The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes.

Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic, or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research.

If the purchaser is unwilling to accept the limitations of this limited use statement, InvivoGen is willing to accept return of the product with a full refund. The product must be returned in resaleable condition. For information on purchasing a license to this product for purposes other than research, contact InvivoGen, 10515 Vista Sorrento Parkway, San Diego, CA 92121 USA. Tel: 858-457-5873 Fax: 858-457-5843.

pCpGfree-vitroBmcs

A CpG-free expression plasmid, containing a multiple cloning site, selectable with Blasticidin

Catalog code: pcpgvtb-mcsg2

https://www.invivogen.com/pcpgfree-vitro-blasticidin

For research use only

Version 20F08-MM

PRODUCT INFORMATION

Contents:

- 20 µg of pCpGfree-vitroBmcs plasmid provided as lyophilized DNA
- *E. coli* GT115 strain provided lyophilized on a paper disk
- 2 x 1 ml blasticidin at 10 mg/ml

Storage and stability:

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store blasticidin at 4°C or -20°C. *

*The expiry date is specified on the product label.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pCpGfree-vitro plasmids represent innovative tools to study the effects of CpG dinucleotides in numerous applications. DNA vaccination exploits the immunostimulatory character of certain CpG motifs to prime and boost the immune response. However, these immunostimulatory CpG motifs are antagonized by CpG dinucleotides in certain distinct base contexts, termed neutralizing CpG motifs. Both types of CpG motifs are usually present in plasmidic DNAs, and therefore may lead to an unfavorable immune response. pCpGfree-vitro is the ideal tool to overcome this problem, and may be used to study the effects of these two types of CpG motifs by adding them in different configurations to the pCpGvitro backbone.

CpG dinucleotides are key elements in a number of cellular functions associated with chromatin. Several large multisubunit complexes, consisting of methyl-CpG binding (MBD) proteins and histone deacetylases, have been implicated in the regulation of chromatin dynamics. These complexes are recruited to methylated CpG dinucleotides by DNA methyl transferases (DNMTs) and induce chromatin remodelling. However the specific roles of these complexes are still to be explored. Due to the absence of CpG dinucleotides within its backbone, pCpGfree-vitro is not the target of DNMTs and thus MBD proteins. Therefore, it provides a useful model to study the other proteins involved in these complexes, in particular the histone deacetylases. It can also be used to analyze the effects of CpG methylation on the regulation and duration of gene expression.

PLASMID FEATURES

pCpGfree-vitro is a family of expression vectors devoid of CpG dinucleotides that are selectable in mammalian cells. All the elements required for replication and selection of the plasmids in bacteria, and gene expression in mammalian cells have been modified to remove all CpG dinucleotides.

- **Composite CpG-free promoter** combining the mouse CMV enhancer, the human elongation factor 1α core promoter and 5'UTR containing a synthetic intron (I 126). This composite promoter yields high and ubiquitous expression of the LacZ gene.
- **MCS:** The multiple cloning site contains the following restriction sites: 5' - BsrG I, Sca I, Bgl II, ApaL I, Bsp120 I, , Nco I, Nhe I, Msc I - 3' Each restriction site is compatible with several other enzymes, increasing the cloning options.
- **CpG-free polyadenylation signals (pAn):** The polyadenylation signals utilized are CpG-free versions of the SV40 late and human β-globin polyadenylation signals. These polyA enable efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA.
- **CpG-free matrix attached regions (MARs)** are AT-rich sequences that are able to form barriers between independent expression cassettes .
- **CpG-free Blasticidin resistance gene (*bsr*-ΔCpG):** The CpG-free blasticidin resistance gene is active both in *E. coli* and mammalian cells.
- **CpG-free SV40 promoter** works in tandem with a bacterial promoter located within a synthetic intron (I-EC2K). This composite promoter drives the expression of the resistance gene in both mammalian cells and *E. coli*.
- **CpG-free *E. coli* R6K gamma origin of replication:** This origin is activated by the R6K specific initiator protein π, encoded by the *pir* gene. Expression of the *pir* gene is necessary for the replication and amplification of pCpGvitro plasmids. *E. coli* GT115 strain expresses a *pir* mutant gene that allows higher plasmid copy number.

1. Wu F. *et al.* 1995. A DNA segment conferring stable maintenance on R6K gamma-origin core replicons. J Bacteriol. 177(22):6338-45. **2. Bode J. *et al.*, 1996.** Scaffold/matrix-attached regions: topological switches with multiple regulatory functions. Crit Rev Eukaryot Gene Expr. 6(2-3):115-38.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H_2O. Store resuspended plasmid at -20°C.

Reconstitution of *E. coli* GT115 strain under sterile conditions

1. Reconstitute *E. coli* GT115 by adding 1 ml of LB medium in the tube containing the paper disk. Let sit for 15 minutes. Mix gently by inverting the tube several times. Let sit 5 more minutes.
2. Streak bacteria taken from this suspension on a LB agar plate.
3. Place the plate in an incubator at 37°C overnight.
4. Isolate a single colony and grow the bacteria in *E. coli* growth medium.
5. Prepare competent cells utilizing your preferred protocol.

Plasmid amplification and cloning:

Plasmid amplification and cloning can be performed in competent *E. coli* GT115.

Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

RELATED PRODUCTS

Product	Description	Cat. Code
ChemiComp GT115 cells	Competent *E. coli* cells	gt115-11
Blasticidin	Selection antibiotic	ant-bl-05

TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com


pCpGfree-vitroBmcs
(5116 bp)
PacI (-1)
AseI (4943)
PacI (4837)
SdaI (427)
Bst1107I (650)
SpeI (857)
HindIII (1081)
BsrGI (1245)
ScaI (1261)
BglII (1268)
ApaLI (1275)
Bsp120I (1282)
NcoI (1289)
NheI (1296)
MscI (1302)
EcoRV (1976)
SwaI (2838)
BspHI (3408)
AseI (3492)
HindIII (3619)
StuI (3638)
SfiI (3682)
SpeI (3784)
EcoRI (4031)
SdaI (4024)
Acc65I (3984)
R6K ori
ßGlo MAR
mCMV enh
EF1 prom
I 126
MCS
SV40 pAn
21q21 S/MAR
ßGlo pAn
bsr ΔCpG
I-EC2K
SV40 enh/prom
IFNß S/MAR

InvivoGen


PacI (-1)
1 TTAATTAAAATTATCTCTAAGGCATGTGAACTGGCTGTCTTGGTTTTCATCTGTACTTCATCTGCTACCTCTGTGACCTGAAACATATTTATAATTCCAT
101 TAAGCTGTGCATATGATAGATTTATCATATGTATTTTCCTTAAAGGATTTTTGTAAGAACTAATTGAATTGATACCTGTAAAGTCTTTATCACACTACCC
201 AATAAATAATAAATCTCTTTGTTCAGCTCTCTGTTTCTATAAATATGTACCAGTTTTATTGTTTTTAGTGGTAGTGATTTTATTCTCTTTCTATATATAT
301 ACACACACATGTGTGCATTCATAAATATATACAATTTTTATGAATAAAAAATTATTAGCAATCAATATTGAAAACCACTGATTTTTGTTTATGTGAGCAA
SdaI (427)
401 ACAGCAGATTAAAAGGAATTTCAATTGCCTGCAGGAGTCAATGGGAAAAACCCATTGGAGCCAAGTACACTGACTCAATAGGGACTTTCCATTGGGTTTT
501 GCCCAGTACATAAGGTCAATAGGGGGTGAGTCAACAGGAAAGTCCCATTGGAGCCAAGTACATTGAGTCAATAGGGACTTTCCAATGGGTTTTGCCCAGT
Bst1107I (650)
601 ACATAAGGTCAATGGGAGGTAAGCCAATGGGTTTTTCCCATTACTGACATGTATACTGAGTCATTAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAG
701 GTCAATAGGGGTGAATCAACAGGAAAGTCCCATTGGAGCCAAGTACACTGAGTCAATAGGGACTTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAG
SpeI (857)
801 GGGGTGAGTCAATGGGTTTTTCCCATTATTGGCACATACATAAGGTCAATAGGGGTGACTAGTGGAGAAGAGCATGCTTGAGGGCTGAGTGCCCCTCAGT
901 GGGCAGAGAGCACATGGCCCACAGTCCCTGAGAAGTTGGGGGGAGGGGTGGGCAATTGAACTGGTGCCTAGAGAAGGTGGGGCTTGGGTAAACTGGGAAA
HindIII (1081)
1001 GTGATGTGGTGTACTGGCTCCACCTTTTTCCCCAGGGTGGGGGAGAACCATATATAAGTGCAGTAGTCTCTGTGAACATTCAAGCTTCTGCCTTCTCCCT
1101 CCTGTGAGTTTGgtaagtcactgactgtctatgcctgggaaagggtgggcaggagatggggcagtgcaggaaaagtggcactatgaacccTGCAGCCCTA
BglII (1268) Bsp120I (1282) NheI (1296)
BsrGI (1245) ScaI (1261) ApaLI (1275) NcoI (1289)
1201 GAcaattgtactaaccttcttctctttcctctcctgacagGTTGGTGTACAGTAGCTTCCAAGTACTAAGATCTAGTGCACAGGGCCCACCATGGAGCTA
MscI (1302)
1301 GCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGC
1401 TTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAA
1501 AGCAAGTAAAACCTCTACAAATGTGGTATGGAATTGGAGCCCCACTGTGTTCATCTTACAGATGGAAATACTGACATTCAGAGGAGTTAGTTAACTTGCC
1601 TAGGTGATTCAGCTAATAAGTGCAAGAAAGATTTCAATCCAAGGTGATTTGATTCTGAAGCCTGTGCTAATCACATTACACCAAGCTACAACTTCATTTA
1701 TAAATAATAAGTCAGCTTTCAAGGGCCTTTCAGGTGTCCTGCACTTCTACAAGCTGTGCCATTTAGTGAACACAAAATGAGCCTTCTGATGAAGTAGTCT
1801 TTTCATTATTTCAGATATTAGAACACTAAAATTCTTAGCTGCCAGCTGATTGAAGGCTGGGACAAAATTCAAACATGCATCTACAACAATATATATCTCA
EcoRV (1976)
1901 ATGTTAGTCTCCAAATTCTATTGACTTCAACTCAAGAGAATATAAAGAGCTAGTCTTTATACACTCTTTAAGGTATGATATCATCTGGAAAGTAACAAAA
2001 TTGATGCAAATTTGAATGAACTTTATCATGGTGTATTTACACAATGTGTTTCTTCTCCCTGCAATGTATTTCTTTCTCTAATTCCTTCCATTTGATCTTT
2101 CATACACAATCTGGTTCTGATGTATGTTTTTTGGATGCACTTTTCAACTCCAAAAGACAGAGCTAGTTACTTTCTTCCTGGTGCTCCAAGCACTGTATTT
2201 GTATCTGTATTCAAGCCCTTTGCAATATTGTACTGGATCATTATTTCACCTCTAGGATGGCTTCCCCAGGCAACTTGTGTTCACCCAGAGACTACATTTT
2301 GTATCTTGTTGACCTTTGAACTTCCACCAGTGTCTAAAAATAATATGTATGCAAAATTACTTGCTATGAGAATGTATAATTAAACAATATAAAAAGGAGA
2401 AGCAAGGAGAGAAACACAGGTGTGTATTTGTGTTTGTGTGCTTAAAAGGCAGTGTGGAAAAGGAAGAAATGCCATTTATAGTGAGGAGACAAAGTTATAT
2501 TACCTCTTATCTGGCTTTTAAGGAGATTTTGCTGAGCTAAAAATCCTATATTCATAGAAAAGCCTTACCTGAGTTGCCAATACCTCAATTCTAAAATACA
2601 GCATAGCAAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTA
2701 GCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGA
SwaI (2838)
2801 CCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAA
2901 GGCCCTTCATAATATCCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCTCTAGCTTTAGTTTCTGG
140◀AsnArgTh
3001 TGTATTTCAGTGGAATCAGCTCCTCAATGGTTGTCTTGACCAGCTTGCCATTCATCTCAATCAGAACAAAGCAATCAGGGGCATAGTCTGAGATGAGCTC
137◀rTyrLysLeuProIleLeuGluGluIleThrThrLysValLeuLysGlyAsnMetGluIleLeuValPheCysAspProAlaTyrAspSerIleLeuGlu
3101 CCTGCACATGCCACAGGGGGACACCACTCTGATGGACCTGTCCACCTCATCACTGTAGGGGTGCCTCACAGCCACAATGGTGTCAAAGTCCTTCTGCCCA
104◀ArgCysMetGlyCysProSerValValArgIleSerArgAspValGluAspSerTyrProHisArgValAlaValIleThrAspPheAspLysGlnGlyA
3201 TTGGAGACTGCAGACCCAATGGCAATGGCCTCTGCACACACAGTGACCCTGCCAATGTAGGCTTCAATGTGGACAGCAGAGATGATTTCTCCTGTCTTGG


3301 TCCTGATGGCAGCACCAACATGGTGCTTGTTGTCCTCATAGAGCATGGTGATTTTCTCAGTGGCAACTTCCACCAGCTCAAGGTCCTGCTGAGAGATGTT
37 rArgIleAlaAlaGlyValHisHisLysAsnAspGluTyrLeuMetThrIleLysGluThrAlaValGluValLeuGluLeuAspGlnGlnSerIleAsn
BspHI (3408)
AseI (3492)
3401 GAAGGTCTTCATGATGGCTCCTCctgtcaggagaggaaagagaagaaggttagtacaattgCTATAGTGAGTTGTATTATACTATGCTTATGATTAATTG
4 PheThrLysMet
3501 TCAAACTAGGGCTGCAgggttcatagtgccacttttcctgcactgccccatctcctgcccacccctttcccaggcatagacagtcagtgacttacCAAACT
HindIII (3619)
StuI (3638)
SfiI (3682)
3601 CACAGGAGGGAGAAGGCAGAAGCTTTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCcAGGgGGCCTgGGC
SpeI (3784)
3701 CTCTGCATAAATAAAAAAAATTAGTCAGCCTGGGGctggggtgggggcaggggtgggggggccaactgggCAGGGGTGGGGGGCCACTAGTGGGACTATGG
3801 TTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATGCATGCTTTG
Acc65I (3984)
3901 CATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCACAGCTGGTTCTTTCAGCCTCAGAAGGTACCTAACCAAGTT
EcoRI (4031)
SdaI (4024)
4001 CCTCTTTCAGAGGTTATTTCAGGCCCTGCAGGAATTCAGTCAATATGTTCACCCCAAAAAAGCTGTTTGTTAACTTGTCAACCTCATTCTAAAATGTATA
4101 TAGAAGCCCAAAAGACAATAACAAAAATATTCTTGTAGAACAAAATGGGAAAGAATGTTCCACTAAATATCAAGATTTAGAGCAAAGCATGAGATGTGTG
4201 GGGATAGACAGTGAGGCTGATAAAATAGAGTAGAGCTCAGAAACAGACCCATTGATATATGTAAGTGACCTATGAAAAAAATATGGCATTTTACAATGGG
4301 AAAATGATGGTCTTTTTCTTTTTTAGAAAAACAGGGAAATATATTTATATGTAAAAAATAAAAGGGAACCCATATGTCATACCATACACACAAAAAAATT
4401 CCAGTGAATTATAAGTCTAAATGGAGAAGGCAAAACTTTAAATCTTTTAGAAAATAATATAGAAGCATGCCATCAAGACTTCAGTGTAGAGAAAAATTTC
4501 TTATGACTCAAAGTCCTAACCACAAAGAAAAGATTGTTAATTAGATTGCATGAATATTAAGACTTATTTTTAAAATTAAAAAACCATTAAGAAAAGTCAG
4601 GCCATAGAATGACAGAAAATATTTGCAACACCCCAGTAAAGAGAATTGTAATATGCAGATTATAAAAAGAAGTCTTACAAATCAGTAAAAAATAAAACTA
4701 GACAAAAATTTGAACAGATGAAAGAGAAACTCTAAATAATCATTACACATGAGAAACTCAATCTCAGAAATCAGAGAACTATCATTGCATATACACTAAA
PacI (4837)
4801 TTAGAGAAATATTAAAAGGCTAAGTAACATCTGTGGCTTAATTAAGTTATCCTAGGAAACCTTAAAACCTTTAAAAGCCTTATATATTCTTTTTTTTCTT
AseI (4943)
4901 ATAAAACTTAAAACCTTAGAGGCTATTTAAGTTGCTGATTTATATTAATTTTATTGTTCAAACATGAGAGCTTAGTACATGAAACATGAGAGCTTAGTAC
5001 ATTAGCCATGAGAGCTTAGTACATTAGCCATGAGGGTTTAGTTCATTAAACATGAGAGCTTAGTACATTAAACATGAGAGCTTAGTACATACTATCAACA
5101 GGTTGAACTGCTGATT